Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating income1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 10, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Amgen Inc. Annual Report.
The Price to Operating Profit (P/OP) ratio for the analyzed period exhibits considerable fluctuation, though generally trends upward over the long term. Initial values are relatively high, followed by a period of decline, and then a resurgence before stabilizing and increasing again in recent years.
- Initial Period (2006-2009)
- The P/OP ratio begins at 17.96 and increases to 19.54 before declining sharply to 9.70. This initial decline likely reflects a combination of factors, potentially including market corrections and changes in investor sentiment. The decrease suggests the share price fell more rapidly than operating profit per share during this period.
- Stabilization and Moderate Growth (2010-2015)
- From 2010 to 2015, the P/OP ratio demonstrates a period of relative stabilization with moderate growth. It fluctuates between approximately 8.79 and 19.13. While there are yearly variations, the ratio generally trends upward, indicating a strengthening relationship between share price and operating profit. The increase to 19.13 in 2015 represents a notable peak within this timeframe.
- Recent Trends (2016-2026)
- The period from 2016 onwards shows a more consistent upward trend in the P/OP ratio. Starting at 13.07, the ratio generally increases, reaching 21.92 by 2026. This suggests that the market has been increasingly willing to pay a premium for each dollar of operating profit. The most recent values, 19.69, 21.55, and 21.92, indicate a sustained high valuation relative to operating profit. The ratio increased from 13.84 in 2020 to 21.92 in 2026.
Overall, the P/OP ratio demonstrates a cyclical pattern with a long-term upward trajectory. The fluctuations suggest sensitivity to market conditions and investor expectations. The recent increase in the ratio may indicate positive investor sentiment regarding future earnings potential or a broader market revaluation.
Comparison to Competitors
| Amgen Inc. | AbbVie Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | |||||||
| Feb 14, 2025 | |||||||
| Feb 14, 2024 | |||||||
| Feb 9, 2023 | |||||||
| Feb 16, 2022 | |||||||
| Feb 9, 2021 | |||||||
| Feb 12, 2020 | |||||||
| Feb 13, 2019 | |||||||
| Feb 13, 2018 | |||||||
| Feb 14, 2017 | |||||||
| Feb 16, 2016 | |||||||
| Feb 19, 2015 | |||||||
| Feb 24, 2014 | |||||||
| Feb 27, 2013 | |||||||
| Feb 29, 2012 | |||||||
| Feb 25, 2011 | |||||||
| Mar 1, 2010 | |||||||
| Feb 27, 2009 | |||||||
| Feb 28, 2008 | |||||||
| Feb 28, 2007 | |||||||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).